BEAM News and Press, Beam Therapeutics Inc. From 11/16/23

2023-11-16 15:54:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...

2023-11-13 06:59:53 ET More on Verve Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve shares surge to three-month high following Q3 update Verve Therapeutics GAAP EPS o...

2023-11-10 16:50:48 ET Summary Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program for Sickle Cell Disease is way behind CRISPR Therap...

2023-11-08 06:46:46 ET More on Beam Therapeutics Beam: Opportunity Based On SCD Data Readout In 2024 Beam Therapeutics: Rich In Cash, Poor In Punctuality (Rating Downgrade) Eli Lilly marks gene editing foray in deal with Beam Editas upgraded at Citi ahead of ...

Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined U...

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, plans to participate in a fireside chat during the 2023 Jef...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Beam Therapeutics Inc. (BEAM) is expected to report $-1.37 for Q3 2023

2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...

2023-11-01 05:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood, the brilliant mind behind ARK Invest , is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, an...